These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1371569)

  • 21. [Importance of specific prostatic antigen to prostatic volume ratio in the selection of patients for ultrasonography-guided biopsy of the prostate].
    Veneziano S; Pavlica P; Querzè R; Viglietta G; Trenta A
    Radiol Med; 1991 Jun; 81(6):857-60. PubMed ID: 1713333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
    Cooper EH; Armitage TG; Robinson MR; Newling DW; Richards BR; Smith PH; Denis L; Sylvester R
    Cancer; 1990 Sep; 66(5 Suppl):1025-8. PubMed ID: 1697498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
    Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF
    Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostatic specific antigen in prostate cancer.
    Wozniak-Petrofsky J
    Urol Nurs; 1992 Sep; 12(3):104-5. PubMed ID: 1382317
    [No Abstract]   [Full Text] [Related]  

  • 25. [PSA in the staging and monitoring of cancer of the prostate].
    Gil Sanz MJ; Sanz Velez JI; Liedana Torres JM; Roncales Badal AL; Allepuz Losa C; Rioja Sanz LA
    Actas Urol Esp; 1991; 15(6):527-31. PubMed ID: 1724347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
    Benson MC; Whang IS; Pantuck A; Ring K; Kaplan SA; Olsson CA; Cooner WH
    J Urol; 1992 Mar; 147(3 Pt 2):815-6. PubMed ID: 1371554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate-specific antigen in prostate cancer.
    Kuriyama M
    Int J Biol Markers; 1986; 1(2):67-76. PubMed ID: 2448397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients.
    Stamey TA; Kabalin JN; Ferrari M; Yang N
    J Urol; 1989 May; 141(5):1088-90. PubMed ID: 2468797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].
    Petrone U; Gaspari G; Marascia G; Magnocavallo N; Petrone D; Tucci C
    Minerva Urol Nefrol; 1990; 42(2):73-5. PubMed ID: 1697431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Digital rectal examination-associated alterations in serum prostate-specific antigen.
    Thomson RD; Clejan S
    Am J Clin Pathol; 1992 Apr; 97(4):528-34. PubMed ID: 1372788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
    Csapo Z; Brand K; Walther R; Fokas K
    J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Isoenzymes of creatine kinase and prostate-specific antigen in the monitoring of prostatic carcinoma].
    Scarazatti E; Lino S; Martinoli F; Borroni A
    Boll Soc Ital Biol Sper; 1990 Jun; 66(6):581-5. PubMed ID: 1701647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of dying from early prostate cancer is low regardless of treatment, study finds.
    White C
    BMJ; 2016 Sep; 354():i4984. PubMed ID: 27633860
    [No Abstract]   [Full Text] [Related]  

  • 34. [Related biomarkers in the diagnosis of prostate cancer].
    Xu YM; Liu HZ
    Zhonghua Nan Ke Xue; 2015 Oct; 21(10):937-40. PubMed ID: 26665686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Specific prostatic antigen: usefulness in clinical practice].
    Isa Kroon WA; Sánchez de la Muela PL; Berian Polo JM
    Med Clin (Barc); 1992 Mar; 98(9):345-7. PubMed ID: 1374824
    [No Abstract]   [Full Text] [Related]  

  • 36. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up.
    Freitas JE; Gilvydas R; Ferry JD; Gonzalez JA
    J Nucl Med; 1991 Jul; 32(7):1387-90. PubMed ID: 1712383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels.
    Yuan JJ; Coplen DE; Petros JA; Figenshau RS; Ratliff TL; Smith DS; Catalona WJ
    J Urol; 1992 Mar; 147(3 Pt 2):810-4. PubMed ID: 1371553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flutamide in hormone-resistant prostatic cancer.
    Fosså SD; Hosbach G; Paus E
    J Urol; 1990 Dec; 144(6):1411-4. PubMed ID: 1700154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
    Fosså SD; Waehre H; Paus E
    Br J Cancer; 1992 Jul; 66(1):181-4. PubMed ID: 1379059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate.
    Schellhammer PF; Schlossberg SM; el-Mahdi AM; Wright GL; Brassil DN
    J Urol; 1991 May; 145(5):1008-10; discussion 1010-1. PubMed ID: 1707987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.